IMPORTANCE Although severe alcohol withdrawal syndrome (SAWS) is associated with substantial morbidity and mortality, most at-risk patients will not develop this syndrome. Predicting its occurrence is important because the mortality rate is high when untreated.
Clinical Scenario
Case A 67-year-old woman was admitted to the emergency department for a minor head laceration that occurred after a fall resulting from alcohol intoxication. She was alert, oriented, looked well, and had a heart rate of 120/min. Her blood alcohol concentration (BAC) was 210 mg/dL (45.6 mmol/L). She reported drinking 8 beers daily for the past 5 years. She was previously admitted to residential addiction treatment programs but never saw an addiction medicine physician. She became mildly tremulous during some, but not all, of her prior attempts at alcohol cessation. She did not have a history of blackouts, withdrawal seizures, delirium tremens, or polysubstance use, including benzodiazepines. Eight hours after her last drink, she looked well, was no longer intoxicated, and her heart rate was unchanged at 120/min. She was otherwise stable and asked about outpatient addiction treatment. Although she appeared well, her physicians were concerned about her risk of developing delirium tremens or alcohol withdrawal seizures when she was discharged home and stopped drinking alcohol. Can risk factors, symptoms, or signs be used to predict the probability of severe alcohol withdrawal syndrome (SAWS)?
Why This Question Is Important
Globally, harmful use of alcohol is responsible for approximately 33 deaths per 100 000 people and 85 million disability-adjusted lifeyears annually. 1 The prevalence of at-risk or heavy alcohol use tends to be higher among adults actively seeking health care than estimated prevalence rates in the general population.
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One serious consequence of chronic alcohol use is the potential for SAWS when its use is reduced or stopped. SAWS is characterized by intense autonomic and psychological symptoms and withdrawal seizures, delirium tremens, or both. SAWS can result in substantial morbidity, including aspiration pneumonia, arrhythmia, and myocardial infarction, 5 and historically was associated with a mortality rate as high as 15%. 6, 7 Recently published data suggest that, with more aggressive prevention and management, SAWS is now associated with mortality rates on the order of a few percent. 8 The National Institute on Alcohol Abuse and Alcoholism and the American Psychiatric Association have developed standardized criteria for atrisk drinking and alcohol withdrawal, respectively (Box 1).
9,11
To prevent SAWS, various pharmacotherapeutic and programmatic strategies such as inpatient withdrawal management have been developed. Appropriate identification, prophylaxis, and treatment of withdrawal is essential in reducing morbidity and mortality associated with this disorder. Although SAWS is relatively uncommon and its treatment costly and risky, the prevalence of at-risk or heavy alcohol use is high, so tools are needed to accurately identify patients at risk of developing SAWS.
Physiologic Basis for Alcohol Withdrawal
The pathophysiology of alcohol withdrawal is incompletely understood. Alcohol is believed to affect the central nervous system (CNS) primarily by facilitating the actions of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain. Alcohol increases the inhibitory effects of the GABA A receptor, while also suppressing the brain's major excitatory neurotransmitter, glutamate, at the N-methyl-D-aspartate (NMDA) receptor. 5 Chronic, heavy alcohol use results in adaptive changes of the GABA and glutamate neurotransmitter systems to compensate for the effects of alcohol on neural pathways and to restore neurochemical equilibrium.
12 Sudden cessation of or a significant reduction in alcohol consumption triggers an acute neurotransmitter imbalance with a rapid decline in inhibitory GABA activity and increased excitatory glutamate and NMDA receptor activity, resulting in overall CNS hyperactivity and a lower threshold for seizures. 12 
Symptoms and Signs Predictive for SAWS
Up to 50% of individuals with a history of long-term, heavy alcohol consumption will experience some degree of mild withdrawal when alcohol use is stopped. [13] [14] [15] Symptoms usually appear during the first 24 hours of abstinence, with autonomic hyperactivity manifesting in tremulousness, racing heart, sweating, nausea, and vomiting. These may be accompanied by psychological symptoms such as anxiety, restlessness, sleep disturbance, or insomnia. Signs of alcohol withdrawal include diaphoresis, tremor, tachycardia, hypertension, hyperthermia, and disorientation. Transient visual, auditory, or tactile hallucinations occur in about 2% to 8% of individuals. 16, 17 While alcohol withdrawal is usually limited to these signs and symptoms, approximately 10% of symptomatic individuals experience withdrawal-related generalized tonic-clonic seizures. 18, 19 If left untreated, about one-third of patients with withdrawal seizures will progress to delirium tremens. 20 Delirium tremens is the most serious manifestation of alcohol withdrawal and is characterized by severe confusion, disorientation, or hallucinations accompanied by severe autonomic hyperactivity. 21 Delirium tremens occurs in 3% to 5% of patients who are hospitalized for the management of alcohol withdrawal. 22, 23 Universal screening for at-risk or heavy drinking of all patients presenting in acute care settings can identify patients who are at increased risk of alcohol-related harms, including SAWS (Box 1). 24, 25 Because patients may underreport the amount and frequency of alcohol use, accurately quantifying alcohol intake is important (eBox 1 in the Supplement). Family members may validate or refute patient reports. Patients meeting criteria for at-risk or heavy drinking should be asked when they last drank. They should be asked about past alcohol cessation attempts and previous withdrawal symptoms. Given the high prevalence of polysubstance use, patients should be asked about use of other substances. Complete blood count, electrolytes, liver function tests, and BAC should be obtained when assessing a patient for alcohol withdrawal. The likelihood of progression to more severe symptoms, seizures, or delirium tremens should be assessed in all patients with alcohol use disorders, even those who are not experiencing withdrawal or whose symptoms are mild.
This Rational Clinical Examination systematically reviewed the diagnostic accuracy of a range of clinical findings used to predict the risk of severe alcohol withdrawal symptoms, seizures, and delirium tremens.
Methods

Search Strategy and Quality Review
Eligible studies compared alcohol use history, symptoms of alcohol withdrawal, laboratory findings, and physical examination findings between patients who did or did not subsequently develop SAWS (eTable 1 in the Supplement). To identify relevant articles, MEDLINE and EMBASE were searched from 1946 to January 2018, using search terms withdrawal, alcohol drinking, the MESH term substance withdrawal syndrome, and terms previously found to be useful for retrieving diagnostic studies (eAppendix in the Supplement). 26 Additional studies were identified by searching reference lists of original and review articles. Studies that evaluated patients' past experiences with alcohol, past symptoms of alcohol withdrawal, and physical examination and laboratory findings were included. Studies were excluded if they only described clinical examination findings for patients with severe withdrawal. Review papers not reporting original data were also excluded.
Two authors (C.J.G., and S.T. or L.A.) independently reviewed abstracts for inclusion in this analysis and assessed study quality using the levels of evidence from The Rational Clinical Examination handbook.
27 Level 1 indicated the highest quality of evidence and was assigned to studies that used an independent blinded comparison of the symptoms or signs with a valid criterion standard for more than 150 consecutive patients. 27 Level 2 studies were similar to level 1 studies but enrolled fewer than 150 patients. Level 3 studies enrolled nonconsecutive patients. Level 4 studies used nonindependent comparisons among a convenience sample of patients at risk of having the condition in question. Sources of bias were also evaluated with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) Tool (eTable 2 in the Supplement).
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Statistical Methods
The population incidence of severe alcohol withdrawal after alcohol cessation was estimated from reports of the US National Institute on Alcohol Abuse and Alcoholism and the World Health Organization.
14,30,31 The incidence of individual alcohol withdrawal symptoms was estimated from the 14 studies included in this review. The summary incidence was calculated as a random-effects estimate from the included studies.
To evaluate the sensitivity, specificity, and likelihood ratios (LRs), 2 × 2 contingency tables were constructed for each symptom and sign. The reliability of symptoms and signs was quantified with the These are the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5) diagnostic criteria for alcohol withdrawal. All 4 must be present to diagnose alcohol withdrawal.
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A. Cessation of (or reduction in) alcohol use that has been heavy and prolonged B. Two (or more) of the following, developing within several hours to a few days after cessation of (or reduction in) alcohol use described in These are the DSM-5 diagnostic criteria for delirium. All 5 must be present to diagnose delirium. The criteria for both alcohol withdrawal and delirium must be met to diagnose alcohol withdrawal delirium, or delirium tremens. A. A disturbance in attention (ie, reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment) B. The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day C. An additional disturbance in cognition (eg, memory deficit, disorientation, language, visuospatial ability, or perception) D. The disturbances in Criteria A and C are not better explained by another preexisting, established, or evolving neurocognitive disorder and do not occur in the context of severely reduced level of arousal, such as coma E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal (ie, due to a drug of abuse or to a medication), or exposure to a toxin, or is due to multiple etiologies
Alcohol Withdrawal Seizure
Typically the generalized tonic-clonic type, characterized by rhythmic, yet jerking movement, especially of the limbs κ statistic. Data were entered into Microsoft Excel spreadsheets predesigned to calculate the sensitivity, specificity, LRs, and their 95% CIs. 32 To create summary measures and limit potential bias, only studies that met the standards of level 1, 2, or 3 of The Rational Clinical Examination criteria were included.
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Rating scales and measures used to define SAWS have traditionally involved a range of criteria (Box 1), but the definition has not been consistent in the literature. 33 For the purpose of this review, we identified cases of SAWS as determined by individual study authors (eTable 1 in the Supplement). Although delirium tremens and seizures may occur as an initial presentation, we considered the manifestations of withdrawal along a continuum from mild to severe withdrawal symptoms that may progress to seizures and delirium tremens. Therefore, if a study reported all 3 outcomes (SAWS, delirium tremens, and seizures), the study result was considered as reporting only an outcome of SAWS to avoid double counting of events within patients. Similarly, if a study reported SAWS and delirium tremens, only SAWS was counted. Finally, if a study reported both delirium tremens and seizure, only delirium tremens was counted.
When a symptom or sign was assessed in only 1 high-quality study, the LRs and 95% CIs were reported for dichotomous variables or the standardized mean difference (SMD) for continuous variables. When a symptom or sign was assessed in 2 studies, the range for the LR or SMD was reported. 34 When considered in 3 studies, LR data were pooled using a separate univariate random-effects meta-analysis, 35 and the I 2 statistic was reported to supplement the information from the CI about the dispersion of results.
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Continuous variables were reported by calculating the SMDs, which reported the differences between patients who developed SAWS and those who did not. The SMD was calculated by dividing the mean difference between groups by the standard deviation of the measurement.
38 Standardized mean differences are unitless, reporting information as multiples of the standard deviation, facilitating comparisons between groups irrespective of the measurement scale. The greater the absolute value of the SMD, the better the differentiation between those who will be affected and those who will not. A general suggestion for interpreting the magnitude of the SMD is to recognize that the SMD is an effect size for which values of approximately 0.2 represent small differences between groups, 0.5 represent moderate differences, and 0.8 or greater indicate potentially large recognizable differences. 39 
Results
Search Results
The systematic search identified 530 studies for review, with 50 articles eligible for qualitative synthesis (eFigure 1 in the Supplement). These 50 studies included patients with a reasonable index of suspicion of alcohol withdrawal risk, ranged in size from 19 to 36 331 patients, and included research and clinical studies of individuals presenting to alcohol withdrawal management units and hospitals, both for alcohol withdrawal and for other reasons (eTable 1 in the Supplement). Of these 50 studies, 14 met the study quality criteria for levels 1 through 3 with bias addressed adequately on most items of the QUADAS tool (eTables 1 to 3 in the Supplement).
28,29
Details of study site characteristics are reported in eTable 1. These 14 higher-quality studies included a total of 71 295 patients and 1355 relevant cases of SAWS (1051 cases), seizure (53 cases), or delirium tremens (251 cases) (eTable 1 in the Supplement).
Incidence of Alcohol Withdrawal Syndrome
The incidence of SAWS was higher in studies designed to assess diagnostic accuracy of risk factors, symptoms, and signs than in populationbased surveys, which reported that less than 1% of the general population experienced severe alcohol withdrawal symptoms in the year prior to being surveyed. 31 The incidence also depended on the patient population, care setting, and reason for admission (ie, inpatient withdrawal management vs general hospital admission). Across 3 studies of patients admitted to withdrawal management facilities, the incidence of SAWS was 23% (95% CI, 20%-27%; I 2 , 0%). [40] [41] [42] The incidence of alcohol withdrawal syndrome of any severity was much lower among at-risk patients admitted to general medical units: 1.9% (95% CI, 1.2-3.1%) among patients with a score greater than 8 on the Alcohol Use Disorders Identification Test (AUDIT) 43 and 6.7% (95% CI, 4.6%-9.6%) among patients with a BAC of more than 200 mg/dL or a history of any drinking in the prior 30 days.
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The incidence of SAWS among general hospitalized patients was low. In consecutive trauma patients, the incidence of SAWS was 0.40% (95% CI, 0.33%-0.48%). 8 In general medical-surgical patients, the incidence of alcohol withdrawal syndrome of any severity was 0.67% (95% CI, 0.58%-0.75%).
44 Among adults with available BAC admitted to a single, academic, tertiary level I trauma center following motor vehicle crashes, 10% (95% CI, 9.3%-11%) developed an alcohol withdrawal syndrome. 45 
Reliability of the Clinical Diagnosis of Alcohol Withdrawal Syndrome
In a survey of 173 patients recruited from inpatient and outpatient substance abuse treatment facilities in the United States, the interrater reliability using the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) 9 criteria for the diagnosis of alcohol withdrawal was excellent (κ, 0.80 [range, 0.71-0.89]). 46 Maldonado et al 2 evaluated the interrater reliability in a random sample of 49 patients and found moderate to substantial agreement in the assessment of risk factors for alcohol withdrawal syndrome (AWS). In a study of a random sample of 103 patients hospitalized with a diagnosis of AWS, interrater reliability between 2 blinded physicians for making the diagnosis was excellent (κ, 0.75 [95% CI, 0.66-0.84]). 44 In a survey of 400 randomly selected patients from 8 regional facilities in the United States, test-retest reliability of the diagnosis of AWS was good to excellent with an interclass correlation coefficient of 0.82 (95% CI, 0.78-0.84). 47 Sullivan et al 48 showedanexcellent interrater reliability using the revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale for the diagnosis of AWS among a random sample of 100 patients (r >0.8). When the same patient was evaluated twice by the same interviewer, testretest reliability was also consistent.
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Risk Factors, Symptoms, and Signs
Risk Factors
A history of delirium tremens was the most frequently studied finding (3 articles) and increased the likelihood that a patient would subsequently develop SAWS after alcohol cessation (summary LR, 2.9 [95% CI, 1.7-5.2]) ( f The 6 independent correlates were use of a morning eye-opener; initial CIWA-Ar score 10 or more; AST 80 or more U/L (to convert to μkat/L, multiply by 0.0167); past benzodiazepine use; history of delirium tremens; and 2 or more prior alcohol treatments. Categories were low risk (0-2 correlates), moderate risk (3), and high risk (4-6).
g LARS-10 is a 10-item rating scale to predict the severity of AWS. Score range, 0 to 14; for which 9 or higher is considered SAWS.
h Rating scale for assessment of AWS (AWS scale) is an 11-item rating scale. Each item is scored from 0 to 3 for somatic symptoms or 0 to 4 for mental symptoms. Score range, 0 to 38, for which 5 or less is considered mild AWS, 6 to 9 is considered moderate AWS, and 10 or higher is considered severe AWS.
i Admission systolic blood pressure is less than 80 mm Hg; respiratory rate, less than 10/min or more than 29/min; or heart rate more than 120/min. Table 2 , eTable 5 in the Supplement), patients who developed SAWS were younger than patients who did not, although the effect size was small (summary SMD, −0.27 [95% CI, −0.49 to −0.05; P = .02]).
Individual studies have reported that patients with a concurrent substance use disorder or mental health condition (eg, mood or anxiety disorder) have an increased risk of SAWS (Table 1 , eTable 6intheSupplement). Based on 3 studies, the absence of a history of delirium tremens had a small effect on identifying patients less likely to develop SAWS (LR, 0.78 [95% CI, 0.67-0.91]). There were no risk factors with a likelihood ratio smaller than 0.5 that would predict the likelihood of not developing SAWS.
Symptoms and Signs
No studies that met our inclusion criteria identified individual symptoms that were useful predictors of SAWS. A systolic blood pressure of 140 mm Hg or higher at admission was associated with increased likelihood of severe alcohol withdrawal (summary LR, 1.7
A normal systolic blood pressure was associated with patients less likely to develop SAWS (LR, 0.78 [95% CI, 0.69-0.89]). However, when evaluated as a continuous measure, those who developed SAWS could not be distinguished by either the systolic blood pressure (range SMD, −0.70 to 0.38) or the diastolic blood pressure (range SMD, −0.47 to 0.32). Although tachycardia is a hallmark of autonomic excitability, the heart rate had a very small effect size for identifying groups of patients more likely to have SAWS (range SMD, 0.01-0.06).
Laboratory Findings
One study suggested that a BAC of more than 200 mg/dL (LR, 3.5 [95% CI, 3.0-4.0]) was associated with increased likelihood of developing alcohol withdrawal. 45 A blood urea nitrogen of more than 26 mg/dL (to convert to millimoles per liter, multiply by 0.357) at admission (LR, 3.3 [95% CI, 1.4-7.6]) was associated with an increased likelihood of developing delirium tremens in another study.
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A third study suggested an association between thrombocytopenia (platelets, <150 × 10 3 /μL) and an increased risk of delirium tremens (LR, 2.2 [95% CI, 1.4-3.4]).
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When evaluated as continuous variables (Table 2) 3 /μL) were associated with patients at risk for SAWS.
Combinations of Symptoms and Signs
Because individual findings had relatively low positive LRs and high negative LRs and effect sizes for continuous variables did not clearly identify patients most likely to have or not have SAWS, several different composite measures were evaluated (Table 1) . In 6 studies, 9 composite measures were used to identify patients at risk of developing SAWS. 2, 8, [40] [41] [42] 50 No composite measures were validated after their initial report. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) (Box 2), which was developed for medically ill inpatients, had the best positive LR and the best negative LR.
2 PAWSS requires recording the presence or absence of 9 risk factors and 1 sign indicating increased autonomic activity (Box 2). Among the PAWSS validation sample, having 4 or more signs or risk factors made SAWS much more likely (LR, 174 [95% CI, 43-696]), whereas having fewer than 4 signs or risk factors was associated with an LR of 0.07 (95% CI, 0.02-0.26). PAWSS sensitivity was 0.93 (95% CI, 0.77-0.99) and specificity was 0.99 (95% CI, 0.98-0.99). Given the baseline incidence rate of approximately 5% among individuals hospitalized for alcohol withdrawal, 23 the positive predictive value (PAWSS, Ն4) would be 93% and the negative predictive value (PAWSS, <4) would be 99% if the PAWSS was validated in new populations.
Prior research has investigated why these instruments seem to have such an effective diagnostic test performance. 55 For PAWSS, incorporation bias is likely because it includes increased autonomic activity in its score. One point on the 10-point PAWSS scale is given when any one of the following is present: heart rate higher than 120/min, tremor, sweating, agitation, or nausea. Of the remaining 9 points, 8 are questions about patients' past experience. Because all questions are weighted equally, further signs of increased autonomic activity would not disproportionately increase the total PAWSS score and would not necessarily be required to obtain a positive score of 4 or higher. Nevertheless, because increased autonomic activity is included in the criteria for diagnosing SAWS, its inclusion in PAWSS likely accounts for PAWSS' high sensitivity and specificity. The Luebeck Alcohol Withdrawal Scale (LARS) 40 relies on a patient's clinical history, physical examination, and laboratory results (eTable 7 in the Supplement). The LARS-10 total score is calculated from 10 findings, yielding a score between 0 and 14. A point is added when any of the following are present: frequent sleep disturbance in the past week, nightmares during the last week, polyneuropathy, ataxia, or BAC of 100 mg/dL or higher. When the BAC is more than 100 mg/dL, an additional point is added for each of the following if present: tremor, sweating, and heart rate of 100/min or higher. Three points are added when there is a history of 3 or more episodes of delirium tremens or 3 or more episodes of withdrawal seizures, for a possible 6 additional points. A score of 9 or more is associated with a greater likelihood of severe withdrawal (LR, 12 [95% CI, 5.8-27]), whereas having a score of less than 9 is associated with an LR of 0.05 (95% CI, 0.02-0.37). The sensitivity of LARS-10 as a test for predicting SAWS is 0.95 (95% CI, 0.77-0.99) and specificity is 0.93 (95% CI, 0.88-0.94). The items considered in a 20-item and an 11-item version of LARS are shown in eTable 7 in the Supplement.
Limitations
This review has several limitations. First, although the literature search yielded 50 original studies reporting information about risk factors for SAWS, only 14 high-quality articles were identified. The 14 articles included more than 70 000 patients and 1300 cases of SAWS, seizure, or delirium tremens. Observational studies examining disease prognosis have potential for bias related to study quality; both The Rational Clinical Examination criteria and the QUADAS tool to assess study quality were used in this review. The quality assessment resulted in the exclusion of 12 of the 17 studies used in an earlier meta-analysis on this topic.
14 Although some biases likely persist, some studies, including the development of PAWSS, involved a range of protections against bias, including a separation between staff assessing study participant PAWSS scores and those diagnosing and treating SAWS.
Second, the current evidence base was developed during an era when treatments that can change the natural history of alcohol withdrawal and prevent SAWS were available. 56 Although not appropriate for all circumstances (eg, the assessment of nonverbal patients), 57 the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) is often used to measure the severity of withdrawal symptoms (ie, not to predict risk of developing future withdrawal) and used to guide administration of benzodiazepine prophylaxis to prevent clinical deterioration. The CIWA can reduce incidence of delirium tremens (−4.9 cases per 100 patients) and seizures (−7.7 seizures per 100 patients). 58 In the present review, use of the CIWA scale was reported in 7 of the 14 higher-quality studies, while the remaining studies used other approaches (eTable 3 in the Supplement). 48 Too much variation between the studies in the CIWA threshold values used to establish a diagnosis of SAWS made a meta-analysis inappropriate (range: Ն8toՆ15) (eTable 1 in the Supplement). A baseline CIWA score appeared useful in a single study 8 and was included among the six independent correlates that constituted a composite measure assessed in Kraemer et al. 42 Although CIWA and other tools affect the natural history of alcohol withdrawal, assessing the accuracy of signs and symptoms is best undertaken in the context of current best practices that include the use of these measures.
Third, the criterion standard for establishing a diagnosis of SAWS was not consistent across studies assessed in this review (eTable 1 in the Supplement). Some studies only assessed components of SAWS rather than the full syndrome. In this review, SAWS was assessed rather than individual symptoms or signs associated with the syndrome.
Scenario Resolution
Case
The patient presented to the emergency department with a known history of alcohol use disorder. Establishing a pretest probability for the incidence of SAWS required clinical judgment and awareness of the variability in outcomes based on the setting and the planned treatment to lower the risk of withdrawal. Since she had a known alcohol use disorder and presented without prolonged sobriety, her risk of developing SAWS in an acute care setting was approximately 5%. 23 If she (Table 1 ) is applied to the pretest probability of 5%, her likelihood of developing SAWS increased to approximately 90%. Based on the findings of this review, she required admission, supportive care, and a therapeutic strategy (eg, benzodiazepine prophylaxis) to prevent the development of SAWS, regardless of the environment considered for assessing pretest risk.
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Clinical Bottom Line Patients admitted to a general medical hospital who have a history of heavy alcohol use have an approximately 2% to 7% chance of developing SAWS. If they are admitted to a specialized treatment center, the likelihood increases to approximately 20%. Individual symptoms or signs do not effectively predict or exclude SAWS. Of the individual findings that can be obtained from a clinical examination, a history of delirium tremens is the most effective finding (summary LR, 2.9 [95% CI, 1.7-5.2]) for predicting SAWS.
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